Amphastar Announces FDA Approval for Ipratropium Bromide HFA

Amphastar Announces FDA Approval for Ipratropium Bromide HFA ELEMENT--[Back to the Newsroom]# Amphastar Announces FDA Approval for Ipratropium Bromide HFARANCHO CUCAMONGA, CA / [ACCESS Newswire]/ February 24, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration ("FDA") has approved the Company's Abbreviated New Drug Application ("ANDA") for Ipratropium Bromide HFA Inhalation Aerosol 17mcg/actuation. The FDA determined that Amphastar's Ipratropium Bromide ...